Acinetobacter News and Research

RSS

Scientists turn to old class of antibiotics to fight superbugs resistant to modern medicine

Scientists at the University at Buffalo are turning to an old class of antibiotics to fight new superbugs resistant to modern medicine.

24 Jun 2014

Cepheid releases molecular test for detection of carbapenemase-producing Gram-negative bacteria

Cepheid today announced the release of Xpert® Carba-R, an on-demand molecular test for rapid and accurate detection of carbapenemase-producing Gram-negative bacteria, to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices.

16 Jun 2014

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced that they have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome) of human patients.

10 Jun 2014

S. pneumoniae is major cause of severe pneumonia in Gambian children

Researchers have published a detailed survey of children with pneumonia in the Gambia, which reveals that Streptococcus pneumoniae is the predominant aetiological agent and that multiple pathogens are present in at least half of cases.

9 Jun 2014

NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV for ABSSSI

The Medicines Company today announced the publication of the results from the SOLO I Phase 3 clinical trial of ORBACTIV (oritavancin), an investigational intravenous antibiotic treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), in the New England Journal of Medicine.

5 Jun 2014

Findings have important implications for improving war wound healing

War wounds that heal successfully frequently contain different microbial species from those that heal poorly, according to a paper published ahead of print in the Journal of Clinical Microbiology.

30 May 2014

MGH researchers test novel approach to disinfecting wounds in animal study

Application of a technology currently used to disinfect food products may help to get around one of the most challenging problems in medicine today, the proliferation of bacteria resistant to antibiotics and other antimicrobial drugs.

22 May 2014

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm Corporation (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead inhaled antibiotic candidate, Pulmaquin®, as a Qualified Infectious Disease Product (QIDP).

20 May 2014

New drug is effective against superbug MRSA

"I routinely call hospitals and request their yearly antibiotic susceptibility testing data," said Washington University in St. Louis' Timothy Wencewicz. "The log might say, for example, that they've treated hundreds of patients for Acinetobacter baumanni, a bacterium brought into U.S. hospitals by soldiers wounded in the Iraq war, with 30 different antibiotics.

6 Mar 2014

Seward highlights effectiveness of Stomacher technique and sponge swabs for hygiene monitoring

Seward Ltd., manufacturers of the world leading range of Stomacher paddle blenders and Stomacher® accessories used in sample preparation for microbiological analyses, have highlighted the highly effective use of its Stomacher technology in combination with sponge swabs for hygiene monitoring and biosecurity applications.

28 Jan 2014

FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

FOB Synthesis, Inc. has entered into a research and development option and license agreement with AstraZeneca for the development of a novel antibiotic to treat drug-resistant bacterial infections.

28 Jan 2014

Hot water contamination in hospital taps threatens patient safety

New research finds significantly higher levels of infectious pathogens in water from faucet taps with aerators compared to water from deeper in the plumbing system. Contaminated water poses an increased risk for infection in immunocompromised patients.

22 Jan 2014

Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

Synthetic Biologics, Inc., a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share.

12 Dec 2013

Researchers identify resistance protein that allows bacteria to survive chlorhexidine

Researchers have identified a resistance protein that allows bacteria to survive chlorhexidine, a disinfectant commonly used in wipes, cleansers and mouthwashes in hospitals.

4 Dec 2013

New type of antibiotic kills multidrug-resistant germ common to health care settings

A new type of antibiotic called a PPMO, which works by blocking genes essential for bacterial reproduction, successfully killed a multidrug-resistant germ common to health care settings, UT Southwestern Medical Center researchers report.

16 Oct 2013

FDA promise to "reboot" antibiotic development rules to combat rise in resistance falls short

The rise of antibiotic resistance among hospital-acquired infections is greater than the Centers for Disease Control and Prevention found in its 2008 analysis, according to an ahead-of-print article in the journal, Antimicrobial Agents and Chemotherapy.

2 Aug 2013

Study reveals that Hudson River polluted with antibiotic-resistant bacteria

The risk of catching some nasty germ in the Hudson River just started looking nastier. Disease-causing microbes have long been found swimming there, but now researchers have documented antibiotic-resistant strains in specific spots, from the Tappan Zee Bridge to lower Manhattan.

22 Jul 2013

BioFire Diagnostics' FilmArray Blood Culture Identification Panel receives FDA clearance

BioFire Diagnostics, Inc., announced today the FDA clearance of its FilmArray Blood Culture Identification Panel. To date, the 27-target panel is the most comprehensive test to be approved by the FDA.

26 Jun 2013

Scientists find way to attack dangerous bacteria that cause eye infections

Much as predators attack their prey in the animal world, there are bacteria that consume and kill other bacteria. Scientists are reporting new progress in putting the predator microbes to work - to attack dangerous bacteria that cause eye infections that lead to blindness and have grown resistant to antibiotics.

21 Jun 2013

Cubist receives Fast Track designation from FDA for late-stage antibiotic candidate

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted the Company's late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product indications, Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections.

8 May 2013